COMPANY

Artiam Bio Inc.

HQ: Morrisville, NC source · artiambio.net ↗

Artiam Bio, Inc. is a biotechnology company that is developing refined type 1 cannabinoid receptor (CB1) antagonists to treat significant diseases. Artiam’s lead compound produces potent-weight loss and hunger-satiety effects in preclinical studies while eliminating adverse effects. From company website Source · Oct 13, 2026

Keywords: cannabinoid receptor preclinical compound

Location: Morrisville, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $280K (STTR Phase I 5R41AG090138-02, continuation, notice Jun 19, 2026). NIH RePORTER 5R41AG090138-02 (Jun 19, 2026)
Evidence (1 event)
- Jun 19, 2026 · NIH RePORTER 5R41AG090138-02
  Organization: ARTIAM BIO INC.; City/State: CARY, NC; Project number: 5R41AG090138-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 279513; Administering IC: National Institute on Aging; Project title: Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 19, 2026 Grant Government grant — STTR: $279,513 (annual award, as published), announced Jun 19, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 19, 2025 Grant Government grant — STTR: $292,279 (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Funding

Last 2 years.

Jun 19, 2026 Government grant — STTR: $279,513 (annual award, as published), announced Jun 19, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 19, 2025 Government grant — STTR: $292,279 (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIA. Source: government award database. source ↗